What is Valitor?
Valitor operates as a specialized biotechnology entity dedicated to the development of advanced ophthalmic medicines. The company leverages its unique multivalent biopolymer platform to engineer treatments that offer extended therapeutic durability, effectively reducing the treatment burden for patients suffering from chronic ocular diseases such as wet age-related macular degeneration (AMD). By prioritizing the development of its lead candidate, VLTR-559, Valitor aims to redefine the standard of care in ophthalmology. The company's market position is bolstered by its ability to bridge the gap between complex biopolymer science and practical clinical application, targeting a high-growth sector within the life sciences industry that demands more efficient, long-lasting therapeutic interventions.
How much funding has Valitor raised?
Valitor has raised a total of $28M across 1 funding round:
Series B
$28M
Series B (2022): $28M with participation from Berkeley Catalyst Fund, ExSight Ventures, First Spark Ventures, Morningside Group, and Pandect Bioventures
Key Investors in Valitor
ExSight Ventures
ExSight Ventures is a leading early-stage venture capital firm specializing in investments in innovative ophthalmic diagnostic and treatment solutions, leveraging the expertise of retinal surgeons.
First Spark Ventures
First Spark Ventures is a Deep Tech venture capital fund that invests in breakthrough technologies aimed at enhancing health, safety, and productivity, with a focus on digital biology and biotech.
Berkeley Catalyst Fund
The Berkeley Catalyst Fund provides funding to startups and helps foster the vibrant startup ecosystem around the UC system and surrounding San Francisco Bay Area.
What's next for Valitor?
With this major enterprise-level funding, Valitor is well-positioned to accelerate the clinical development of its pipeline and refine its biopolymer delivery systems. The strategic roadmap likely involves advancing VLTR-559 through critical regulatory milestones while simultaneously exploring collaborative opportunities to expand its technological footprint into broader therapeutic areas. As the company transitions from early-stage research to more robust clinical validation, the focus will remain on scaling its operational capabilities and securing its intellectual property portfolio. This capital injection provides the necessary runway to sustain long-term R&D efforts, ensuring that Valitor remains a competitive force in the evolving landscape of ocular therapeutics and biotechnology innovation.
See full Valitor company page
